Details for Patent: 9,018,243
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
Which drugs does patent 9,018,243 protect, and when does it expire?
Patent 9,018,243 protects OTEZLA and is included in one NDA.
This patent has eighty patent family members in twenty-three countries.
Summary for Patent: 9,018,243
Title: | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, compositions thereof, and uses thereof |
Abstract: | Solid forms comprising (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoi- soindoline-1,3-dione, compositions comprising the solid forms, methods of making the solid forms and methods of their use are disclosed. The methods include methods of treating and/or preventing disorders ameliorated by the reduction of levels of TNF-.alpha. or the inhibition of PDE4. |
Inventor(s): | Muller; George W. (Rancho Santa Fe, CA), Schafer; Peter H. (Belle Mead, NJ), Man; Hon-Wah (Princeton, NJ), Ge; Chuansheng (Belle Mead, NJ), Xu; Jean (Warren, NJ) |
Assignee: | Celgene Corporation (Summit, NJ) |
Application Number: | 14/102,407 |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 9,018,243 |
Patent Claim Types: see list of patent claims | Use; |
Drugs Protected by US Patent 9,018,243
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Amgen Inc | OTEZLA | apremilast | TABLET;ORAL | 205437-001 | Mar 21, 2014 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIASIS | See Plans and Pricing | |||
Amgen Inc | OTEZLA | apremilast | TABLET;ORAL | 205437-001 | Mar 21, 2014 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF ADULT PATIENTS WITH ORAL ULCERS ASSOCIATED WITH BEHCET'S DISEASE | See Plans and Pricing | |||
Amgen Inc | OTEZLA | apremilast | TABLET;ORAL | 205437-001 | Mar 21, 2014 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | TREATMENT OF ADULT PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS | See Plans and Pricing | |||
Amgen Inc | OTEZLA | apremilast | TABLET;ORAL | 205437-001 | Mar 21, 2014 | AB | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | USE OF OTEZLA (APREMILAST) FOR THE TREATMENT OF PSORIATIC ARTHRITIS | See Plans and Pricing | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 9,018,243
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Austria | 440599 | See Plans and Pricing | |||
Australia | 2003224729 | See Plans and Pricing | |||
Canada | 2479666 | See Plans and Pricing | |||
Canada | 2756798 | See Plans and Pricing | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |